drugset / Trial / NCT00039780
Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel
Phase 3
Completed
764 enrolled
BioNumerik Pharmaceuticals, Inc.
Lantern Pharma Inc. became Sponsor of Tavocept (BNP7787) IND 051014 as of March 26, 2019. · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine whether BNP7787 is effective in preventing or reducing neurotoxicity (nerve damage) caused by paclitaxel (Taxol®).
Timeline
- Start
- 2001-09
- Primary completion
- 2006-10
- Completion
- 2014-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | 2,2'-DITHIODIETHANESULFONIC ACID | Small molecule | 18400 mg/m2 | — |